Learning about the safety and effectiveness of Zavicefta in Korea

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather data on the safety and effectiveness of Zavicefta after its market release in Korea. It focuses on patients with complicated intra-abdominal infections, complicated urinary tract infections, and hospital-acquired pneumonia. The study will monitor adverse events and drug reactions in real-world clinical settings, as mandated by the Ministry of Food and Drug Safety (MFDS) of Korea. Participants will include both adults and pediatric patients who have received Zavicefta for their infections.

Why it matters

Who can join: the full rules

1. Adults and paediatric patients aged 3 months and older, who have been administered at least one dose of Zavicefta for the treatment of one of the indications as follows:

   * Complicated intra-abdominal infection (cIAI)
   * Complicated urinary tract infection (cUTI), including pyelonephritis
   * Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)
   * Other aerobic Gram-negative organism infection with limited treatment options
2. Adults 19 years of age or older, who have been administered at least one dose of Zavicefta for the treatment of the indication as follows:

   •Bacteremia associated with or suspected to be associated with cIAI, cUTI or HAP including VAP.
3. Patients are treated with Zavicefta for the first time
4. Patients have signed the data privacy statement.

Where it's running

• Pfizer
  Seoul, Gangnam-gu, South Korea Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pneumonia After Heart Surgery: Can AI Predict It?

  This study tests whether artificial intelligence can predict hospital-acquired pneumonia after heart surgery and whether pneumonia can indicate higher risk of future heart and lung problems.

  Recruiting Tomsk National Research Medical Center of the Russian Academy of Sciences · Tomsk · NCT07745491

• Predictors and Outcomes of Ventilated Hospital-Acquired Pneumonia

  This study looks at which factors predict outcomes for patients with ventilated hospital-acquired pneumonia to help guide care.

  Recruiting Assiut University · Asyut, Asyut Governorate · NCT07667582

• Using dexamethasone to treat severe hospital-acquired pneumonia in critically ill patients

  This study is testing if adding dexamethasone to standard treatment helps critically ill patients with severe hospital-acquired pneumonia feel better compared to those who only get standard treatment.

  Recruiting at 19 sites Phase 3 Nantes University Hospital · Amiens and 33 other locations · NCT06269900

• Using acyclovir to treat pneumonia in ventilated patients with herpes simplex virus

  This study is testing if giving acyclovir to ICU patients on ventilators who have pneumonia and herpes simplex virus can help them survive better than those who don't receive the medication.

  Recruiting at 28 sites Phase 3 Jena University Hospital · Freiburg im Breisgau, Baden-Wurttemberg and 27 other locations · NCT06134492

• Early treatment with targeted antibiotics for severe infections using rapid diagnostics

  This study is testing if giving targeted antibiotics right away, based on quick test results, can help hospitalized patients with severe infections caused by tough-to-treat bacteria feel better faster than standard care.

  Recruiting at 21 sites Phase 4 National University of Singapore · Vellore and 20 other locations · NCT05979545

• Investigating cefepime-enmetazobactam for treating complicated urinary tract infections in children

  This study is testing a new combination of antibiotics to see if it can safely and effectively treat complicated urinary tract infections in children who are in the hospital.

  Recruiting at 4 sites Phase 2 Orchid Pharma Europe GmbH · Hradec Králové and 7 other locations · NCT05826990

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.